Abstract
During winter months, there is increased pressure on health care systems in temperature climates due to seasonal increases in respiratory illnesses. Providing real-time short-term forecasts of the demand for health care services helps managers plan their services.
During the Winter of 2022-23 we piloted a new forecasting pipeline, using existing surveillance indicators which are sensitive to increases in respiratory syncytial virus (RSV). Indicators including telehealth cough calls and ED bronchiolitis attendances, both in children under 5 years. We utilised machine learning techniques to train and select models that would best forecast the timing and intensity of peaks up to 28 days ahead. Forecast uncertainty was modelled usings a novel gamlss approach which enabled prediction intervals to vary according to the level of the forecast activity.
The winter of 2022-23 was atypical because the demand for healthcare services in children was exceptionally high, due to RSV circulating in the community and increased concerns around invasive Group A streptococcal (GAS) infections. However, our short-term forecasts proved to be adaptive forecasting a new higher peak once the increasing demand due to GAS started. Thus, we have demonstrated the utility of our approach, adding forecasts to existing surveillance systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Institute for Health Research (NIHR). This work also benefits from the infrastructure and partnerships assembled by Health Data Research UK, including through the Data and Connectivity National Core Study, funded by UK Research and Innovation [grant reference MC_PC_20058].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in this study were anonymised. The UKHSA has access to a range of data sources under Regulation 3 (Health Protection) of the Health Service (Control of Patient Information) Regulations 2002. The requirement for specific ethics approval for use of these data in health protection research is therefore waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Applications for requests to access relevant anonymised data included in this study should be submitted to the UKHSA Office for Data Release. Available at: https://www.gov.uk/government/publications/accessing-ukhsa-protected-data.
